

PET imaging request

PET/CT available at: **City West**
Windsor Gardens

Level 3, 18 North Terrace, Adelaide - Tel 8115 9600 Fax 8115 9699
Level 1, 480 North East Road - Tel 8766 3000 Fax 8766 3099

Appointment details

Time	Date
------	------

Patient details

Name	DOB
Address	Weight (kg) Height (cm)
	Diabetic <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> IDDM <input type="checkbox"/> NIDDM
Telephone (M)	Claustrophobic <input type="checkbox"/> Yes <input type="checkbox"/> No

Clinical indication

Primary site of the disease

Recent chemotherapy Date Recent radiotherapy Date and region

Date (or approximate date) of follow up with specialist

Medicare clinical indications - for full descriptions, please see back of form

Brain (FDG) <input type="checkbox"/> 61560 - Alzheimer's disease <input type="checkbox"/> 61538 - Brain tumour <input type="checkbox"/> 61559 - Epilepsy	Lung <input type="checkbox"/> 61523 - SPN <input type="checkbox"/> 61529 - NSCLC Staging
Breast Cancer <input type="checkbox"/> 61524- Staging (Stage III Cancer) <input type="checkbox"/> 61525 - Suspected metastatic or recurrent	Melanoma <input type="checkbox"/> 61553 - Suspected residual, metastatic or recurrent
Cervix Cancer <input type="checkbox"/> 61571- Staging (Stage IB2) <input type="checkbox"/> 61575 - Recurrence	Oesophageal or Junctional Gastric <input type="checkbox"/> 61577 - Staging
Colorectal Cancer <input type="checkbox"/> 61541- Suspected residual, metastatic or recurrent	Ovarian Cancer <input type="checkbox"/> 61565 - Suspected residual, metastatic or recurrent
Head and Neck Cancer <input type="checkbox"/> 61598 - Staging new or recurrent <input type="checkbox"/> 61604 - Suspected residual	Prostate Cancer (PSMA) <input type="checkbox"/> 61563 - Staging (Intermediate or High Risk) - PSA level <input type="checkbox"/> 61564 - Restaging - PSA level
Lymphoma (Hodgkin or Non Hodgkin) <input type="checkbox"/> 61620- Staging <input type="checkbox"/> 61622- Response to treatment <input type="checkbox"/> 61628 - Recurrence/Restaging <input type="checkbox"/> 61632 - Pre stem cell transplant	Rare and Uncommon Cancers (including unknown primary) <input type="checkbox"/> 61612 - Staging <input type="checkbox"/> 61614 - Suspected residual, metastatic or recurrent
Other: (Non-Medicare eligible indications) Please specify	Sarcoma (excluding GIST) <input type="checkbox"/> 61640 - Staging <input type="checkbox"/> 61646 - Suspected residual or recurrent
	SCC <input type="checkbox"/> 61610 - Unknown primary involving cervical nodes

Additional diagnostic imaging required

In addition to PET/CT, a full diagnostic CT Brain Neck Chest Pelvis Abdomen Other region

MRI Region +/- U/S guided cannulation if required


Recent correlative imaging

Referrer details (must be specialist referred for a Medicare rebate)


<input type="checkbox"/> CT Date Imaging provider	Provider number
<input type="checkbox"/> MRI Date Imaging provider	Doctor's name Telephone
<input type="checkbox"/> Other Date Imaging provider	Signature Date

Your doctor has recommended that you use Benson Radiology. Any change to this recommendation should be discussed with your doctor first.

City West Level 3, 18 North Terrace, Adelaide
 Tel 8115 9600 Email citywest@bensonradiology.com.au
 Free patient parking on level 3 of 18A, the multi-storey carpark directly behind our building (enter off Newmarket St)



Windsor Gardens Level 1, 480 North East Road
 Tel: 8766 3000 Email: windsorgardens@bensonradiology.com.au
 Ample free parking available on site



Staging/diagnosis

BREAST Whole body FDG PET study for the staging of locally advanced (Stage III) breast cancer in a patient considered suitable for active therapy

SOLITARY PULMONARY NODULE Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed

NON-SMALL CELL LUNG CANCER Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned

MELANOMA Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy

CERVIX Whole body FDG PET study, for the further primary staging of patients with histologically proven carcinoma of the uterine cervix, at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent

OESOPHAGEAL AND JUNCTIONAL GASTRIC Whole body FDG PET study, performed for the staging of proven oesophageal or GEJ carcinoma, in patients considered suitable for active therapy

HEAD & NECK Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head and neck cancer

SQUAMOUS CELL CARCINOMA NECK NODES Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cervical nodes

LYMPHOMA: HODGKIN'S OR NON-HODGKIN'S Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin's or non-Hodgkin's lymphoma

SARCOMA Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable

EPILEPSY FDG PET study of the brain, performed for the evaluation of refractory epilepsy which is being evaluated for surgery

BRAIN FDG PET for the diagnosis of Alzheimer Disease (limit 1 per year, 3 per lifetime)

PSMA Whole body PSMA PET for staging of intermediate to high-risk prostate adenocarcinoma for a previously untreated patient. Maximum one service per lifetime

RARE AND UNCOMMON CANCERS Whole body FDG PET study for the initial staging of eligible* rare cancer types for a patient who is considered suitable for active therapy. Applicable once per cancer diagnosis

* To review eligible cancers please visit bensonradiology.com.au/rarecancer

Restaging or surveillance

BREAST Whole body FDG PET study for evaluation of suspected metastatic or recurrent breast carcinoma in a patient considered suitable for active therapy

COLORECTAL CARCINOMA Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy

MELANOMA Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy

OVARIAN CANCER Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy

HEAD & NECK RESTAGING Whole body FDG PET study performed for the evaluation of patients with suspected residual head and neck cancer after definitive treatment, and who are suitable for active therapy

HEAD & NECK RECURRENCE Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head and neck cancer

LYMPHOMA RESPONSE Whole body FDG PET study to assess response to first line therapy either during treatment or within three months of completing definitive first line treatment for Hodgkin's or non-Hodgkin's lymphoma

LYMPHOMA RECURRENCE Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin's or non-Hodgkin's lymphoma

LYMPHOMA PRE TRANSPLANT Whole body FDG PET study to assess response to second-line chemotherapy when stem cell transplantation is being considered, for Hodgkin's or non-Hodgkin's lymphoma

CERVIX Whole body FDG PET study, for the further staging of patients with confirmed local recurrence of carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent

BRAIN TUMOUR FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy

SARCOMA Whole body FDG PET study for the evaluation of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent

PSMA Whole body PSMA PET for restaging of recurrent prostate adenocarcinoma for a patient that has undergone prior therapy (PSA increase of 2ng/mL after radiotherapy, failure of PSA to fall to undetectable levels, rising PSA after radical prostatectomy). Maximum two services per lifetime.

RARE AND UNCOMMON CANCERS Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent cancer in a patient who is undergoing, or is suitable for, active therapy